Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

1.905 -0.465 (-19.62%)
Streaming Delayed Price Updated: 2:39 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' ↗
U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower. 
Via Benzinga
News headline image
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗
 
Via Benzinga
News headline image
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
News headline image
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
News headline image
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Top movers in Thursday's pre-market session ↗
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne ↗
Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025. 
Via Benzinga
News headline image
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
News headline image
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for November 14th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Via ACCESSWIRE
News headline image
Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.